Sotagliflozin for T1D and Other ADCES Highlights
This episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives (https://www.hcplive.com/podcasts/diabetes-dialogue) , our second related to the Association of Diabetes Care and Education Specialists (ADCES) 2024 annual meeting, spotlights new data and perspectives from the meeting brought forth by pharmaceutical and diabetes technology companies. Check out our first epi...
21m Aug 21, 2024
21m
First 10 Prices Announced from CMS Price Negotiations
On August 15, 2024, the Biden-Harris Administration announced the price list for the first 10 drugs selected as part of the Medicare price negotiations between the United States Department of Health and Human Services (HHS) and pharmaceutical manufacturers. “Americans pay too much for their prescription drugs. That makes today’s announcement historic. For the first time ever, Medicare negotiate...
8m Aug 19, 2024
8m
Navigating ADCES 2024
The Association of Diabetes Care and Education Specialists (ADCES) is an organization ahead of its time in the world of healthcare. Often, those in medicine find the field to be reactionary instead of proactive in addressing the rising burden of chronic disease. The ADCES, formerly the American Association of Diabetes Educators, was founded in 1973 to support and educate clinicians, care provid...
25m Aug 19, 2024
25m
SUMMIT and FINEARTS-HF, with Muthiah Vaduganathan, MD, MPH
In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP,  welcome Muthiah Vaduganathan, MD, MPH, cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital, for a discussion around topline data updates from the SUMMIT and FINEARTS-HF trials, the latter of which Vaduganathan served on as a trial investigator. Video Version:...
23m Aug 10, 2024
23m
Simplera CGM and Medtronic's Partnership with Abbott
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives (https://www.hcplive.com/podcasts/diabetes-dialogue) , hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes ...
14m Aug 10, 2024
14m
CATALYST Trial and Hypercortisolism in T2D, with John Buse, MD, PhD
Even with the second half of the trial yet to be completed, results of the CATALYST trial have initiated a potentially seismic shift in discussions around the management of type 2 diabetes (https://www.hcplive.com/clinical/type-2-diabetes) . With the first part of the trial suggesting approximately 1-in-4 patients with difficult-to-control type 2 diabetes, results suggest hypercortisolism could...
24m Aug 02, 2024
24m
New Early-Stage T1D Monitoring Guidance, with Anastasia Albanese-O'Neill, PhD, APRN
Less than a month after rebranding from JDRF to Breakthrough T1D, the leading type 1 diabetes (https://www.hcplive.com/clinical/type-1-diabetes) advocacy organization has now released new consensus guidance related to the monitoring of early-stage type 1 diabetes. Debuted on the final day of the 84th American Diabetes Association Scientific Sessions (https://www.hcplive.com/conference/ada) , th...
21m Jul 18, 2024
21m
INHALE-3 and Diabetes Tech Updates, with Grazia Aleppo, MD
At the 84th American Diabetes Association (ADA) Scientific Sessions (https://www.hcplive.com/conference/ada) , INHALE-3 was among the trials to take center stage. A phase 4 trial comparing the use of inhaled insulin (Afrezza) against standard care, results demonstrated use of inhaled insulin, in addition to insulin degludec, was associated with improved HbA1c in patients with type 1 diabetes (h...
25m Jul 18, 2024
25m
Blue Circle Health, with Monica Gomberg, MD
Despite being a chronic autoimmune disease, the burden of type 1 diabetes (https://www.hcplive.com/clinical/type-1-diabetes) is often overlooked in public health discussions. Not only are patients with type 1 diabetes being tasked with understanding disease pathophysiology as an integral part of optimal management, but also with keeping up with advances in pharmacotherapy and technology. As a ...
18m Jul 18, 2024
18m
Advances in AID and CGM at ADA 2024, with Davida Kruger, NP
In this special edition episode from the 84th American Diabetes Association Scientific Sessions (https://www.hcplive.com/conference/ada) , hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Davida Kruger, NP, a certified nurse practitioner in the Division of Endocrinology at Henry Ford Health System in Detroit. During the episode, Kruger takes hosts on a deep dive into the lat...
24m Jul 18, 2024
24m
ADA Introduces Obesity Association, with Robert Gabbay, MD, PhD
On the opening day of the 84th American Diabetes Association Scientific Sessions (https://www.hcplive.com/conference/ada) , the ADA ushered in a new era for their organization with the announcement of the formation of the Obesity Association. Created more than a decade after the American Medical Association recognized obesity (https://www.hcplive.com/clinical/obesity-management) as a disease, t...
12m Jul 18, 2024
12m
Patient Considerations for Inhaled Insulin, with Carol Levy, MD
In this special edition recorded at the 84th American Diabetes Association Scientific Sessions (https://www.hcplive.com/conference/ada) , Carol Levy, MD, director of the Mount Sinai Diabetes Center and Type 1 Diabetes Clinical Research, joins the podcast for a deep dive into the INHALE-3 trial and how to incorporate individual patient-level factors into the management strategy of patients with ...
18m Jul 18, 2024
18m
ADA 2024 Diabetes Technology Recap
This special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives (https://www.hcplive.com/podcasts/diabetes-dialogue) focuses on top highlights and updates in diabetes technology from the 84th American Diabetes Association Scientific Sessions (https://www.hcplive.com/conference/ada) . In the episode, hosts Omnipod 5 and the SECURE-T2D trial, a study compar...
32m Jul 18, 2024
32m
June 2024 Updates in Diabetes Technology and T1D
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a June 2024 update focusing on a trio of topics across the spectrum of diabetes management. In the episode, hosts discuss the US Food and Drug Administration clearance of 2 new over-the-counter continuous glucose monitoring systems from Abbott...
24m Jun 17, 2024
24m
GLAM and CRISTAL, Updates in Pregnancy
In this episode, hosts provide their audience with an overview of a pair of new studies on the topic of diabetes in pregnancy: the GLAM and CRISTAL studies.
21m Jun 05, 2024
21m
FLOW Trial and Semaglutide's Benefit in Chronic Kidney Disease
To celebrate the FLOW trial and break down what it means for people with type 2 diabetes and CKD, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, recorded a special edition episode to discuss the clinical application of this trial, unmet need in CKD management, the future of incretin therapies, and more! Chapters: 00:00 - Intro 00:40 - FLOW Background 02:55 - FLOW Results 07:08 - Combina...
14m May 31, 2024
14m
2024 ACP Type 2 Diabetes Recommendations
The American College of Physicians has released new recommendations in favor of SGLT2i and GLP-1 RA and against the use of DPP-4i as second-line therapies to metformin in adults with type 2 diabetes and inadequate glycemic control. Released on the first day of the ACP’s Internal Medicine Meeting 2024 (https://www.hcplive.com/conference/acp) , the pair of recommendations reflect the findings fro...
24m Apr 20, 2024
24m
STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies
In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, tackle a pair of related topics: what the STEP HFpEF DM trial from ACC.24 means for the diabetes community and the need for fair and equitable allocation of incretin-based therapies in the face of ongoing drug shortages and overwhelming demand.
24m Apr 20, 2024
24m
What to Know about Sequel Med Tech's twiist AID System, with Alan Lotvin, MD
The diabetes community welcomed an additional tool to the armamentarium with the US Food and Drug Administration’s clearance of the twiist automated insulin delivery (AID) system on March 18, 2024. Cleared for use in patients aged 6 years and older with type 1 diabetes (https://www.hcplive.com/clinical/type-1-diabetes) , the twiist, which is marketed by Sequel Med Tech, is billed as the first d...
31m Mar 30, 2024
31m
Hot Topics and Updates from ATTD 2024
In the third and final recap episode from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes, hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives (https://www.hcplive.com/podcasts/diabetes-dialogue) Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into a series of topics from the meeting, including GLP-1 recept...
21m Mar 30, 2024
21m
T1D Glycemic Improvement and CRISTAL at ATTD 2024
In this episode, hosts provide insight from automated insulin delivery updates from the 17th annual International Conference on Advanced Technologies & Treatments for Diabetes. The specific topics of note covered in this study include new data related to diabetes technology use from the Type 1 Diabetes (T1D) Exchange and a read-out of data from the CRISTAL trial.
8m Mar 26, 2024
8m
FLOW Trial and Chronic Kidney Disease Updates, with Brendon Neuen, MBBS, PhD
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives (https://www.hcplive.com/podcasts/diabetes-dialogue) hosts are joined by Brendon Neuen, MBBS, PhD, nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and senior research fellow at The George Institute for Global Health. During the episode, Neuen talks about the FLOW trial, t...
30m Mar 22, 2024
30m
Dexcom Stelo and CGM Updates, with Jake Leach
Hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives (https://www.hcplive.com/podcasts/diabetes-dialogue) recorded a special edition episode with Jake Leach, chief operating officer of Dexcom. The episode itself represents a follow-up to a conversation a year ago at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 2023, where Leach di...
28m Mar 22, 2024
28m
Tirzepatide and the Future of Incretin Therapies, with Timothy Garvey, MD
W. Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham and the principal investigator of SURMOUNT-2, joins our hosts to provide perspective on several topics, including the FDA’s approval of tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and m...
25m Mar 18, 2024
25m
SELECT, Semaglutide, & the Future of Incretin Therapies, with A. Michael Lincoff, MD
In this episode, hosts are joined by co-chair of the SELECT steering committee A. Michael Lincoff, MD, to discuss results, potential explanations for cardiovascular benefit of semaglutide 2.4 mg beyond weight reduction, FLOW trials implications, and the future of incretin therapies. Chapters: 00:35 - Guest Introduction 01:10 - SELECT Results Overview 04:25 - Next Steps for Research 07:15 - Mec...
25m Mar 02, 2024
25m
Understanding MARD, Comparing Popular CGM Sensors
In this episode, the hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors. Video version: https://www.hcplive.com/view/diabetes-dialogue-understanding-mard-comparing-popular-cgm-sensors Key Highlights: 00:35 - The Myth of MARD 04:10 - Considerations When Inte...
22m Feb 29, 2024
22m
ATTD 2024 Preview
In the episode, hosts provide insight into sessions to watch, device news they are excited for, what makes ATTD a unique and valuable experience for the diabetes care team, and how the meeting’s annual yearbook session encapsulates the exciting developments within the field. Video Version: https://www.hcplive.com/view/diabetes-dialogue-attd-2024-preview Key Highlights: 01:05 - Bellini’s ATT...
15m Feb 26, 2024
15m
Time in Range, CGM Metrics for Predicting Outcomes in Diabetes
The introduction of CGM in 1999 completely shifted the trajectory of care for people with diabetes. Now, new data suggest advanced CGM metrics, such as time in range, are proving comparable to HbA1c for predicting diabetic retinopathy and other microvascular outcomes. In this episode, Viral Shah, MD, joins Diabetes Dialogue to discuss a recent study examining associations between time in range...
15m Feb 20, 2024
15m
Tirzepatide in Type 1 Diabetes, with Viral Shah, MD
In this episode, hosts are joined by Shah for a discussion on his recent proof-of-concept study looking at tirzepatide in type 1 diabetes, the prospect of GLP-1 RA-based therapies in type 1 diabetes, and the potential roles for tirzepatide beyond T2D and weight management. Episode Highlights 00:00 - Intro 01:56 - Use of GLP-1s in T1D 05:32 - Study on Tirzepatide in T1D 10:04 - Insulin Use in ...
17m Feb 15, 2024
17m
Diabetes Technology Updates in January 2024
In this episode, hosts discuss recent news and updates in diabetes technology from Abbott, Dexcom, and Medtronic in the first half of January 2024. Episode Highlights 00:40 Abbott FreeStyle Libre 2 Plus 18:08 Dexcom Stelo 26:30 Medtronic Simplera Sync
30m Jan 10, 2024
30m
Updates in Management of Hypercortisolism in Type 2 Diabetes, with Ralph DeFronzo, MD
In this episode, hosts sit down with Ralph DeFronzo, MD, for a discussion on how advances in management have transformed the diagnosis and management of hypercortisolism among people with type 2 diabetes. Episode Highlights 00:39 DeFronzo Introduction 01:54 Presentation of Hypercortisolism 05:50 Ominous Octet and Hypercortisolism 09:47 Prevalence of Hypercortisolism in T2D 13:57 Impact of Unt...
32m Jan 09, 2024
32m
Latest Updates on Diabetes Management in Pregnancy
In this episode, the hosts break down a pair of recent studies published in JAMA examining use of non-insulin agents in the management of diabetes during pregnancy. Episode Highlights 00:05 Intro 00:28 Episode Overview 02:00 GLP-1 RAs in Early Pregnancy 05:53 Implications of Results 10:30 Metformin in Early Pregnancy 13:48 Implications of Results
20m Jan 08, 2024
20m
Baricitinib & the Potential Disease-Modifying Therapies in Type 1 Diabetes
Hosts discuss a recent study on baricitinib in type 1 diabetes, how these results compare to other data in this arena, and what all of these studies mean for future of type 1 diabetes management. Episode Highlights 00:05 Intro 01:20 Baricitinib Overview 02:30 BANDIT Trial Design 03:30 Trial Results 05:40 Delaying Type 1 Diabetes 14:45 Need for Screening 18:00 Outro
18m Jan 03, 2024
18m
Diabetes Dialogue: 2023 Top Episodes Recap
To celebrate the end of 2023, hosts recap the top 10 episodes of the past year and offer perspective on how the news discussed in these episodes has shaped the future of diabetes management. Episode Highlights 00:32 Automated Insulin Delivery News in October 2023 04:35 Breaking Down AACE's New Type 2 Diabetes Management Algorithms 06:45 What Medicare Drug Price Negotiations Mean for Diabetes 0...
30m Jan 01, 2024
30m
Key Updates in ADA Standards of Care—2024
Hosts discuss what they consider the most significant or relevant updates in the ADA's Standards of Care—2024, with a focus on new recommendations for glycemic management, bone health, immunizations, and weight management. Episode Highlights 0:05 Intro 1:04 Glycemic Management Updates 9:00 Bone Health Updates 13:30 Immunization and Vaccination Updates 15:35 Weight Management Updates 23:10 Outro
23m Dec 29, 2023
23m
Diabetes Technology Updates and Standards of Care—2024
In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the latest in diabetes technology from December 2023, with a spotlight on announcements surrounding use of Dexcom’s G7 continuous glucose monitoring (CGM) system as well as the latest updates to the American Diabetes Association’s Standards of ...
23m Dec 19, 2023
23m
SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023
In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.
16m Nov 11, 2023
16m
Tirzepatide (Zepbound) Approved for Chronic Weight Management
In this episode, hosts discuss the FDA's approval of tirzeptiade (Zepbound) as an adjunct to lifestyle modification for the chronic weight management in people with overweight or obesity.
15m Nov 08, 2023
15m
Diabetes Dialogue: Automated Insulin Delivery News in October 2023
In this episode, hosts discuss the FDA clearance of the Omnipod 5 App for iPhones and a pair of studies examining use of automated insulin delivery systems.
25m Nov 01, 2023
25m
SURMOUNT-3 and SURMOUNT-4 Data
In this episode, hosts discuss the results of SURMOUNT-3 and SURMOUNT-4 as well as how it might help inform use of tirzepatide if approved by the US Food and Drug Administration for chronic weight management.
22m Oct 27, 2023
22m
PROTECT Data and Teplizumab in Newly Diagnosed T1D
In this episode, hosts discuss data from the PROTECT trial, which examined the effects of teplizumab on beta-cell function in patients with newly diagnosed type 1 diabetes.
15m Oct 25, 2023
15m
Accu-Chek Solo and Abbott Acquiring Bigfoot Biomedical
In this episode, hosts discuss a pair of topics making headlines in recent weeks: the US Food and Drug Administration’s 510(k) clearance for the Accu-Chek Solo micropump system and Abbott’s acquisition of Bigfoot Biomedical.
22m Sep 19, 2023
22m
Making Sense of Semaglutide in Type 1 Diabetes
In this episode, hosts sit down for a discussion around a recent NEJM report assessing the effects of semaglutide use in people with type 1 diabetes, including the implications of the findings and their real-world experiences with GLP-1 use in people with type 1 diabetes. Video version: https://www.hcplive.com/view/diabetes-dialogue-making-sense-of-semaglutide-in-type-1-diabetes
18m Sep 08, 2023
18m
Clearance of Tandem Mobi and Welldoc's BlueStar Platform
Hosts discuss their experience interacting with the Tandem Mobi pump from the ADCES 2023 meeting and offer perspective on what the Welldoc clearances mean for people with diabetes and care providers. Video Version: https://www.hcplive.com/view/diabetes-dialogue-tandem-mobi-and-welldoc-bluestar-platform
21m Sep 02, 2023
21m
Addressing Health Disparities with Diabetes Technology, with Etty Vider, PharmD
Hosts are joined by Etty Vider, PharmD, for a nuanced discussion surrounding leveraging diabetes technology to improve care for people with diabetes, including exploring strategies for improving the utilization of diabetes technology, the role of primary care in adoption of these technologies, and how improved uptake correlates to improved outcomes. Video version: https://www.hcplive.com/view/...
19m Sep 02, 2023
19m
What Medicare Drug Price Negotiations Mean for Diabetes
In this special edition episode, hosts break down what the announcement of the 10 drugs selected for Medicare price negotiations under the Inflation Reduction Act means for providers and people with diabetes. The 4 diabetes agents included on the list, which were empagliflozin, dapagliflozin, sitagliptin, and Novo Nordisk-branded insulin products, accounted for more than $16 billion in Part D s...
17m Aug 29, 2023
17m
Diabetes Dialogue: The Role of Nutrition in Diabetes Management, with Dawn Noe, RDN, LD
In this episode, Isaacs and Bellini sit down with Dawn Noe, RDN, LD, for a discussion surrounding her journey into diabetes care, the importance of individualizing nutrition in diabetes management, and the sessions she led and moderated at ADCES 2023. Video version: https://www.hcplive.com/view/diabetes-dialogue-the-role-of-nutrition-in-diabetes-management-with-dawn-noe-rdn-ld
26m Aug 23, 2023
26m
Diabetes Dialogue: Implications of SELECT Trial and Brenzavvy on Cost Plus Drugs
In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial. Video version: https://www.hcplive.com/view/diabetes-dialogue-implications-of-select-trial-and-brenzavvy-on-cost-plus-drugs
33m Aug 23, 2023
33m
Diabetes Dialogue: ADCES 2023 Recap
In this episode, which is the first of multiple special edition ADCES 2023 episodes, hosts hold an overarching discussion of the meeting itself and major themes from the ADCES's 50th-anniversary celebration. Video version: https://www.hcplive.com/view/diabetes-dialogue-adces-2023-recap
22m Aug 23, 2023
22m
Diabetes Dialogue: ADA 2023 Recap
After a whirlwind conference packed with special episodes and late-breaking data, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss their top takeaways from ADA 2023. Video version: https://www.hcplive.com/view/diabetes-dialogue-ada-2023-recap
33m Aug 23, 2023
33m